The latest price target for Contineum Therapeutics (NASDAQ:CTNM) was reported by RBC Capital on November 7, 2024. The analyst firm set a price target for $31.00 expecting CTNM to rise to within 12 months (a possible 136.64% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Contineum Therapeutics (NASDAQ:CTNM) was provided by RBC Capital, and Contineum Therapeutics maintained their outperform rating.

There is no last upgrade for Contineum Therapeutics

There is no last downgrade for Contineum Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Contineum Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Contineum Therapeutics was filed on November 7, 2024 so you should expect the next rating to be made available sometime around November 7, 2025.

While ratings are subjective and will change, the latest Contineum Therapeutics (CTNM) rating was a maintained with a price target of $32.00 to $31.00. The current price Contineum Therapeutics (CTNM) is trading at is $13.10, which is out of the analyst’s predicted range.